Effect of short-term continuous subcutaneous insulin infusion treatment on beta-cell function, blood fat and C-reactive protein of newly diagnosed type 2 diabetes mellitus patients
10.3760/cma.j.issn.1008-6315.2014.08.024
- VernacularTitle:短期持续皮下胰岛素输注对初诊2型糖尿病患者胰岛功能、血脂及C反应蛋白的影响
- Author:
Xiaohui YU
- Publication Type:Journal Article
- Keywords:
Type 2 diabetes mellitus;
Continuous subcutaneous insulin infusion;
Beta-cell function;
Blood lipid;
C-reactive protein
- From:
Clinical Medicine of China
2014;30(8):863-865
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect on short-term continuous subcutaneous insulin infusion (CSII) treatment on beta-cell function,serum triglyceride(TG),C-reactive protein(CRP) and serum insulin like growth factor-1 (IGF-1) of newly diagnosed type 2 diabetes mellitus(T2DM) patients.Methods Thirty-two newly diagnosed T2DM patients with fasting plasma glucose(FPG) ＞ 11.1 mmol/L were treated with CSII for 2 weeks.FPG,2 h postprandial blood glucose (2hPG),fasting insulin (FINS),2 h postprandial insulin (PINS),fasting C peptide (FC-P),2 h postprandial C peptide (PC-P),glycosylated hemoglobin (HbA1 c),Homa-β,Homa-R,TG,CRP and IGF-1 were measured and compared before and after CSII.Results (1) Compared with that of before treatment,the levels of FPG,2hPG,HbA1c,PINS and PC-P in patients after treatment were dramatically improved(t =12.04,11.57,7.61,20.77,6.16; P ＜ 0.05),and Homa-β increased from (23.0 ±16.2) to (71.0±23.8)(t=9.46,P＜0.05),while Homa-IR significantly decreased from (6.8 ±2.1) to (3.9 ± 2.6) (t =4.81,P ＜ 0.05).(2) The levels of TG and CRP significantly decreased from (1.50 ± 0.32) mmol/L,(3.14±1.14) to (1.29±0.31) mmol/L,(1.95 ±0.52) mg/L(t =26.73,23.62;P ＜0.05).The levels of IGF-1 significantly increased from (341 ± 16) μg/L to (471 ± 17) μg/L (t =8.65,P ＜ 0.05).Conclusion The excellent glycemic control,improvement of lipid metabolism,anti-inflammatory and improvement of beta-cell function can be achieved with short-term CSII intensive therapy in newly diagnosed T2DM patients with severe hyperglycemia.
